Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows

Abstract

With the introduction of direct-acting antiviral agents (DAA), the rate of sustained virological response (SVR) in the treatment of hepatitis C virus (HCV) has radically improved to over 95%. Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of cirrhosis, resulting in a decreased incidence of hepatocellular carcinoma (HCC). However, a debate on the impact of DAAs on the development of HCC is ongoing. This review aimed to analyse the scientific literature regarding the risk of HCC in terms of its recurrence and occurrence after the use of DAAs to eradicate HCV infection. Among 11 studies examining HCC occurrence, the de novo incidence rate ranged from 0 to 7.4% (maximum follow-up: 18 mo). Among 18 studies regarding HCC recurrence, the rate ranged from 0 to 54.4% (maximum "not well-defined" follow-up: 32 mo). This review highlights the major difficulties in interpreting data and reconciling the results of the included studies. These difficulties include heterogeneous cohorts, potential misclassifications of HCC prior to DAA therapy, the absence of an adequate control group, short follow-up times and different kinds of follow-up. Moreover, no clinical feature-based scoring system accounts for the molecular characteristics and pathobiology of the tumours. Nonetheless, this review does not suggest that there is a higher rate of de novo HCC occurrence or recurrence after DAA therapy in patients with previous HCV infection.

Keywords: Direct-acting antiviral agents; Hepatitis C virus; Hepatocellular carcinoma; Occurrence; Recurrence.

Figure 1

Hepatocellular carcinoma cumulative occurrence rates reported by 11 studies considered in the present review. HCC: Hepatocellular carcinoma; f.u.: Follow up; NA: Not available.

Figure 2

Hepatocellular carcinoma cumulative recurrence rates reported by 17 studies considered in the present review. HCC: Hepatocellular carcinoma; f.u.: Follow up; NA: Not available.